Nwam LLC Sells 3,454 Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Nwam LLC trimmed its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 11.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,629 shares of the company’s stock after selling 3,454 shares during the quarter. Nwam LLC’s holdings in Teva Pharmaceutical Industries were worth $418,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Rehmann Capital Advisory Group boosted its stake in Teva Pharmaceutical Industries by 8.8% in the 3rd quarter. Rehmann Capital Advisory Group now owns 9,814 shares of the company’s stock worth $211,000 after purchasing an additional 795 shares during the period. Hancock Whitney Corp boosted its position in shares of Teva Pharmaceutical Industries by 7.8% during the 4th quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock valued at $186,000 after acquiring an additional 868 shares during the last quarter. Financial Counselors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 0.7% during the 4th quarter. Financial Counselors Inc. now owns 124,805 shares of the company’s stock valued at $1,924,000 after acquiring an additional 872 shares during the last quarter. Hartford Investment Management Co. boosted its position in shares of Teva Pharmaceutical Industries by 3.1% during the 4th quarter. Hartford Investment Management Co. now owns 29,581 shares of the company’s stock valued at $456,000 after acquiring an additional 902 shares during the last quarter. Finally, Cigna Investments Inc. New boosted its position in shares of Teva Pharmaceutical Industries by 5.9% during the 4th quarter. Cigna Investments Inc. New now owns 17,342 shares of the company’s stock valued at $267,000 after acquiring an additional 959 shares during the last quarter. 67.01% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on TEVA shares. HSBC set a $12.00 price target on Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Tuesday, February 5th. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 14th. Credit Suisse Group decreased their price objective on Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, February 14th. UBS Group assumed coverage on Teva Pharmaceutical Industries in a report on Thursday, March 7th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, SunTrust Banks began coverage on Teva Pharmaceutical Industries in a report on Tuesday, March 19th. They set a “hold” rating and a $17.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $20.53.

Shares of NYSE TEVA traded down $0.11 during mid-day trading on Friday, hitting $14.36. 5,940,946 shares of the stock traded hands, compared to its average volume of 10,158,394. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66. Teva Pharmaceutical Industries Ltd has a 52 week low of $14.04 and a 52 week high of $25.96. The firm has a market capitalization of $14.71 billion, a PE ratio of 5.13, a P/E/G ratio of 1.81 and a beta of 1.30.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The company had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.38 billion. During the same period in the previous year, the company posted $0.94 earnings per share. The firm’s revenue was down 15.2% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.27 earnings per share for the current year.

In other news, VP Richard Daniell sold 2,098 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $35,414.24. Following the completion of the transaction, the vice president now owns 2,098 shares in the company, valued at $35,414.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $69,326.16. Following the completion of the transaction, the insider now owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The disclosure for this sale can be found here. Insiders sold 16,691 shares of company stock worth $283,458 over the last three months. Corporate insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Nwam LLC Sells 3,454 Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/teva-pharmaceutical-industries-ltd-teva-position-trimmed-by-nwam-llc.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Special Dividends

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.